HeartSciences Total Non-Operating Income/Expense 2022-2025 | HSCS
HeartSciences total non-operating income/expense from 2022 to 2025. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
| HeartSciences Annual Total Non-Operating Income/Expense (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $0 |
| HeartSciences Quarterly Total Non-Operating Income/Expense (Millions of US $) |
|
|---|---|
| 2025-01-31 | $0 |
| 2024-10-31 | $0 |
| 2024-07-31 | $0 |
| 2024-04-30 | $0 |
| 2024-01-31 | $0 |
| 2023-10-31 | $0 |
| 2023-07-31 | $0 |
| 2023-04-30 | $0 |
| 2023-01-31 | $0 |
| 2022-10-31 | $0 |
| 2022-07-31 | $0 |
| 2022-04-30 | $0 |
| 2022-01-31 | $0 |
| 2021-10-31 | $0 |
| 2021-07-31 | $0 |
| 2021-04-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MEDICAL INFO SYS | $0.004B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||